Liminatus Pharma agreed to acquire CAR-T biotech InnocsAI in a stock deal valued at $320 million, gaining access to an oncology pipeline centered on bivalent CD19xCD22 CAR-T. InnocsAI’s lead asset IBC101 is targeted at relapsed or refractory B-cell malignancies and already has IND clearance to start a Phase 1/2 study at a hospital in Korea. The portfolio also includes a preclinical bicistronic CAR-T (INC101) using mesothelin as a primary activation signal and B7-H3 as a secondary signal, aiming to improve tumor selectivity by requiring two tumor-associated cues. The acquisition underscores how CAR-T developers are continuing to consolidate antigen coverage and platform features to differentiate next-generation candidates.